Riboxx Completes GMP Manufacture of Ligand for Immuno-Oncology Therapeutics

The German biotech company can now supply its proprietary ligand on a GMP industrial-scale for clinical applications in immune-oncology.
Sep 12, 2017
By BioPharm International Editors

On Sep. 12, 2017, Riboxx Pharmaceuticals, a German biotech company specializing in the development of toll-like-receptor (TLR) and RIG-I-like-receptor (RLR) ligands, and Accinov, a biomanufacturing center located in Lyon, France, announced the manufacture, including packaging and quality control, of Riboxxim, a potent TLR3-ligand, on an industrial scale and in compliance with good manufacturing practices (GMP). Riboxx manufactured the ligand using its patented Tenpora process according to European Union GMP requirements.

Riboxxim is the company’s experimental immuno-oncology drug that activates the innate immune system to eliminate cancer cells. It has been validated in pre-clinical studies for immunotherapy of cancer. It is available for clinical applications in immune-oncology and therapeutic vaccines.

Source: Riboxx Pharmaceuticals

native1_300x100
lorem ipsum